Anixa’s FSHR-Targeted CAR-T Shows Positive Safety, Patients Surpass Median Survival
Anixa Biosciences, Inc. (NASDAQ: ANIX), in partnership with Moffitt Cancer Center, announced the completion of dosing in the fourth...
Chimeric Endocrine Receptor-T (CER-T)
Advertisement
Advertisement
